Research shows why pharma and biotech now account for 70% of materiovigilance leadership, 84% of organizations are outsourcing critical activities, while 97% are impacted by a challenge many consider to be extreme.
Join IQVIA and Citeline for an exclusive first look at findings from the 2025 Materiovigilance and Technology Adoption Survey, based on insights from senior leaders directly responsible for device safety, regulatory oversight, and vigilance operations. This insightful webinar unpacks what the data reveals about current capability gaps, emerging operational pressures, and how pharma and biotech organizations are responding as materiovigilance becomes a strategic priority.
Key takeaways include:
- Shifting Ownership: Why pharma and biotech now lead materiovigilance as combination products and digital therapies expand device safety responsibilities.
- Capability Gaps: Where organizations managing combination products are struggling with expertise, governance, and operational readiness.
- Regulatory Pressure: How global requirements for combination products and SaMD are creating widespread compliance strain.
- Outsourcing Strategy: Why outsourcing has become a core approach for scaling combination product vigilance and inspection readiness.
- Technology Momentum: How automation and AI are shaping the future of materiovigilance, and why data readiness remains a hurdle.
Speaker Details
Dr Padmalakshmi Jnaneshwar
Director, Safety Operations, Lifecycle Safety, IQVIA
Shamayeeta Chakravarty
Manager, Safety Operations, Medical Devices, IQVIA
Ildephonse Ngabonziza
Associate Director, Safety Operations, Medical Devices, IQVIA
Rajalakshmi Sangoji
Associate Director, Regulatory Reporting, Medical Devices, IQVIA
Inspire. Connect. Innovate.
